Financial Performance - As of March 31, 2023, the company had cash and cash equivalents of HKD 207.5 million, down from HKD 241.3 million in 2022[30]. - The total revenue for the year ended March 31, 2023, was approximately HKD 213.8 million, a decrease of about HKD 11.4 million or 5.1% compared to HKD 225.2 million for the year ended March 31, 2022[176]. - For the fiscal year ending March 31, 2023, the company recorded a loss of approximately HKD 3.2 million, compared to a profit of HKD 13.5 million for the previous year[138]. - Cash generated from operating activities for the year ended March 31, 2023, was HKD 16.2 million, a decrease from HKD 27.6 million in the previous year, primarily due to a pre-tax loss of approximately HKD 2.9 million[107]. - The company reported a net loss of HKD 3,191 thousand for the year ended March 31, 2023, compared to a profit of HKD 13,491 thousand in the previous year[168]. Waste Management and Environmental Sustainability - The group generated 173.9 kg of medical waste during the reporting period, with a density of 0.00081 kg per thousand dollars of revenue[31]. - The total hazardous waste produced was 120.0 kg, with a density of 0.00056 kg per thousand dollars of revenue, meeting the established target[31]. - The overall density of hazardous waste was 0.00137 kg per thousand dollars of revenue, slightly deviating from the previous target due to the introduction of chemical waste[31]. - The company emphasizes the importance of proper packaging for medical waste to prevent leakage and ensure safety during handling[32]. - The company is committed to environmental sustainability and has implemented energy-saving measures to optimize resource usage[62]. Risk Management - The company’s board is responsible for evaluating and determining the nature and extent of risks it is willing to take to achieve its strategic objectives[8]. - The company has adopted multiple risk management procedures and guidelines to define implementation authority for key business processes and office functions[9]. - The company has identified potential climate-related risks, including acute risks like extreme weather and chronic risks such as sustained high temperatures, which could lead to business and supply chain disruptions, resulting in decreased revenue[87]. Employee and Labor Relations - The total number of employees as of March 31, 2023, is 136, with a gender breakdown of 114 males and 22 females[93]. - The employee turnover rate in Hong Kong is 44%, with a significantly higher turnover rate of 108% for employees aged 50 and above[94][95]. - The company is committed to complying with all relevant labor laws and regulations, ensuring a diverse and inclusive work environment[89]. - Employee benefits expenses for the year ended March 31, 2023, were approximately HKD 52.6 million, accounting for 24.6% of revenue, up from HKD 42.0 million or 18.7% in the previous year[104]. Business Development and Expansion - The group plans to acquire equity interests in ophthalmology clinics and hospitals in China to expand its "Clear" brand business[127]. - The company is exploring opportunities for mergers and acquisitions and partnerships in the Greater Bay Area to expand its market presence[149]. - The establishment of new medical centers is expected to strengthen the company's service network and consolidate its leadership position in the Hong Kong ophthalmology industry[176]. Financial Position and Liquidity - As of March 31, 2023, the net current assets were HKD 193.5 million, down from HKD 225.4 million as of March 31, 2022[107]. - The group maintained a cash balance to manage financial obligations, indicating no significant liquidity risk[121]. - As of March 31, 2023, the current ratio was 5.8 times, down from 10.3 times as of March 31, 2022, reflecting a decrease in liquidity[130]. - The group has maintained a net cash position as of March 31, 2023, with no outstanding bank loans or borrowings[130]. Revenue Breakdown - The average revenue from refractive surgery services accounted for approximately 64.4% of total revenue for the year ended March 31, 2023[158]. - Revenue from SMILE surgery was HKD 3,944 thousand, representing 77.5% of total revenue, an increase from 72.7% in the previous year[157]. - Revenue from refractive surgery decreased by approximately HKD 14.8 million or 9.7% to about HKD 137.8 million for the year ended March 31, 2023, primarily due to a decline in multifocal intraocular lens replacement surgery revenue[196]. - Revenue from other eye treatments increased by approximately HKD 3.3 million or 6.0% to about HKD 58.4 million for the year ended March 31, 2023, accounting for 27.4% of total revenue[196]. Professional Fees and Expenses - Professional fees increased by approximately HKD 4.2 million or 381.8%, from about HKD 1.1 million for the year ended March 31, 2022, to about HKD 5.3 million for the year ended March 31, 2023[105]. - Other expenses increased from approximately HKD 24.2 million in 2022 to HKD 31.8 million in 2023, accounting for 10.7% and 14.9% of revenue respectively[186]. - Business development expenses rose by approximately HKD 1.5 million or 25.0% from about HKD 6.0 million in 2022 to about HKD 7.5 million in 2023[187].
清晰医疗(01406) - 2023 - 年度财报